ERBB2 and breast cancer: The primary objective was to compare the pCR rate of the standard neoadjuvant treatment combination of docetaxel, trastuzumab, and pertuzumab (DTP) with T-DM1 monotherapy in ERBB2-positive breast cancer patients.